49.26

0.50% -0.25

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $49.26, with a volume of 3.33M. It is down -0.50% in the last 24 hours and down -9.21% over the past month. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Previous Close:

$49.51

Open:

$49.82

24h Volume:

3.33M

Relative Volume:

1.54

Market Cap:

$9.15B

Revenue:

$2.69B

Net Income/Loss:

$-214.04M

P/E Ratio:

-42.10

EPS:

-1.17

Net Cash Flow:

$98.43M

1W Performance:

-0.10%

1M Performance:

-9.21%

6M Performance:

-17.46%

1Y Performance:

-22.17%

1-Day Range:

$48.76

$50.98

1-Week Range:

$45.94

$51.45

52-Week Range:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1169)

Industry

Diagnostics & Research (60)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

7,000

Twitter

@exactsciences

Next Earnings Date

2024-11-05

Latest SEC Filings

EXAS's Discussions on Twitter

Compare EXAS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXAS Exact Sciences Corp	49.26	9.15B	2.69B	-214.04M	98.43M	-1.17
TMO Thermo Fisher Scientific Inc	532.55	203.70B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	210.23	151.18B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	135.37	38.62B	6.51B	1.29B	1.37B	4.42
IDXX Idexx Laboratories Inc	452.77	37.07B	3.90B	887.87M	808.08M	10.67
IQV Iqvia Holdings Inc	191.04	33.64B	15.41B	1.37B	2.11B	7.50

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-25	Initiated	Barclays	Overweight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Buy
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

Feb 21, 2025

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga

Feb 21, 2025

Feb 20, 2025

Exact Sciences Corp Earnings Call Highlights Growth - TipRanks

Feb 20, 2025

Exact Sciences Has an Established Colon Cancer Screening Franchise and a Progressing Pipeline - Morningstar

Feb 20, 2025

Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga

Feb 20, 2025

TD Cowen sees upside in Exact Sciences stock, maintains $86 target - Investing.com

Feb 20, 2025

Exact Sciences stock price target cut to $65 at BTIG - Investing.com

Feb 20, 2025

Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025

Exact Sciences stock price target cut to $65 at BTIG By Investing.com - Investing.com South Africa

Feb 20, 2025

Exact Sciences Reports Robust Q4 Earnings, Surpassing Revenue ProjectionsNews and Statistics - IndexBox, Inc.

Feb 20, 2025

Exact Sciences (EXAS) PT Lowered to $65 at BTIG - StreetInsider.com

Feb 20, 2025

Exact Sciences: Q4 Earnings Snapshot - mySA

Feb 20, 2025